Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic

While the potential therapeutic utility of angiotensin-converting enzyme 2 (ACE2) is well established, the clinical development of ACE2 drugs has been limited, likely due in part to the short half-life of the protein. In contrast, Ig-like ACE2 fusion proteins have exhibited greatly extended plasma h...

Full description

Saved in:

Bibliographic Details
Published in:	mAbs Vol. 12; no. 1; p. e1782600
Main Authors:	Qian, Kewen, Hu, Shi
Format:	Journal Article
Language:	English
Published:	Taylor & Francis 01-01-2020 Taylor & Francis Group
Subjects:	diffuse alveolar damage Ig-like proteins neutralization Other SARS-CoV SARS-CoV-2
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	While the potential therapeutic utility of angiotensin-converting enzyme 2 (ACE2) is well established, the clinical development of ACE2 drugs has been limited, likely due in part to the short half-life of the protein. In contrast, Ig-like ACE2 fusion proteins have exhibited greatly extended plasma half-life in vivo, and they have been shown to have a potent neutralization effect against SARS-CoV-2. Clinical investigation of Ig-like ACE2 fusion proteins as COVID-19 interventions is thus warranted.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1942-0862 1942-0870
DOI:	10.1080/19420862.2020.1782600